Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19950462 | 0.86 | WDR5 (0.37) | WDR5OPRM1 | |
| SCHEMBL15459020 | 0.86 | OPRM1 (0.40) | WDR5OPRM1 | |
| SCHEMBL23802062 | 0.82 | WDR5 (0.38) | WDR5OPRM1 | |
| SCHEMBL2674905 | 0.82 | WDR5 (0.38) | WDR5 | |
| SCHEMBL31646560 | 0.80 | WDR5 (0.49) | WDR5 | |
| SCHEMBL3206919 | 0.79 | KMT2A (0.45) | WDR5OPRM1 | |
| SCHEMBL25347409 | 0.79 | WDR5 (0.40) | WDR5 | |
| SCHEMBL19031018 | 0.79 | WDR5 (0.40) | WDR5OPRM1 | |
| SCHEMBL1502809 | 0.78 | CYP11B2 (0.39) | WDR5OPRM1 | |
| SCHEMBL2300 | 0.77 | OPRM1 (0.46) | WDR5OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024217523-A1 | SELECTIVE TKY2 INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2024-10-24 | — | — | WO | disclosed |
| US-11306084-B2 | Integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2022-04-19 | — | — | US | disclosed |
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | Indalo Therapeutics, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | Indalo Therapeutics, Inc. | 2019-11-14 | — | — | US | disclosed |
| EP-3562826-A1 | INTEGRIN ANTAGONISTS | Saint Louis University (US) | 2019-11-06 | — | — | EP | disclosed |
| CN-110177787-A | Integrin antagonists | 圣路易斯大学 | 2019-08-27 | — | — | CN | disclosed |
| WO-2018132268-A1 | INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2018-07-19 | — | — | WO | disclosed |
| EP-2875021-B1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | UNIV SAINT LOUIS (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2875021-B1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | UNIV SAINT LOUIS (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9085606-B2 | Beta amino acid derivatives as integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| CN-102099335-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | disclosed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2215089-A1 | [1H- PYRAZOLO [3, 4-B]PYRIDINE-4-YL]-PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA | Vertex Pharmaceuticals Incorporated (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| WO-2009073300-A1 | [1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291937-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | WDR5 2731/4885OPRM1 4289/4885 |
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | ITGA5, ITGB5, ITGB2 | WDR5 4049/4885OPRM1 549/4885 |
| US-20120149680-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | WDR5 2731/4885OPRM1 4289/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | WDR5 1560/4885OPRM1 1051/4885 |
| US-11306084-B2 | Integrin antagonists | ITGA5, ITGB5, ITGB2 | WDR5 4049/4885OPRM1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.